Previous 10 | Next 10 |
2023-07-19 11:00:00 ET Summary Pharmaceuticals/biotechnology is the most attractive subsector regarding both value and quality scores. Healthcare equipment is the most overpriced healthcare industry. Fast facts on iShares U.S. Healthcare ETF. 10 healthcare stocks cheaper t...
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics PR Newswire Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned ...
2023-06-21 15:17:56 ET Summary Innoviva Inc. shares have slightly outperformed the S&P 500, returning about 12% against a gain of about 10.8% for the S&P 500. The company has promising developments and the financials are "fine," but the shares are not cheap, making the ris...
2023-06-19 05:16:46 ET Summary Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on PBE, a genomics ETF. 10 healthcare stocks cheaper than their peers in Ju...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will present at the Goldman Sachs Annual Global Healthcare Conference in Dana Point, CA o...
2023-05-26 15:00:30 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
2023-05-24 06:03:52 ET Innoviva ( NASDAQ: INVA ) said the the U.S. Food and Drug Administration (FDA) approved bacterial pneumonia therapy Xacduro. The new drug application (NDA) for Xacduro (sulbactam for injection; durlobactam for injection) was filed by Entasis Th...
Indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter First pathogen-targeted therapy addressing Acinetobacter, including resistant strains, an emerging global health threat and gro...
2023-05-22 05:00:00 ET Summary Pharmaceuticals/biotechnology and healthcare providers still have good value scores. Healthcare equipment is the less attractive subsector. Fast facts on IHF, a healthcare providers ETF. 10 stocks cheaper than their peers in May. ...
Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) . ...
News, Short Squeeze, Breakout and More Instantly...
2024-05-12 00:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Core royalty platform on track; receiving GSK royalties of $61.9 million Achieved net product revenues of $19.1 million, representing 66% year-over-year growth driven by launch of XACDURO® and growth of key core product GIAPREZA® Strong pipeline progress: positive Phase ...
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strate...